Atara Biotherapeutics (AT20) Drug Pipeline
| Drug Name | Condition | Stage | Status | Study Name | Trial Start Date | Article |
|---|---|---|---|---|---|---|
| Ata3219 | Lupus Nephritis, Systemic Lupus Erythematosus | Phase I | Withdrawn | A Study to Evaluate the Safety and Preliminary Efficacy of ATA3219 in Participants With Systemic Lupus Erythematosus | May 21, 2024 | ― |
| Ata3219 | Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma | Phase I | Terminated | A Study to Evaluate the Safety and Preliminary Efficacy of ATA3219 in Participants With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma | Feb 05, 2024 | ― |
| Pembrolizumab, Tabelecleucel, Tab-Cel | Nasopharyngeal Carcinoma, Nasopharyngeal Neoplasms, Epstein-Barr Virus Infections, Epstein-Barr Viraemia, Epstein-Barr Virus-Associated Nasopharyngeal Carcinoma (Ebv+ Npc) | phase1AndPhase2 | Terminated | Tabelecleucel in Combination With Pembrolizumab in Subjects With Epstein-Barr Virus-associated Nasopharyngeal Carcinoma (EBV+ NPC) | Nov 29, 2018 | ― |
| Tab-Cel, Ebvallo, Tabelecleucel | Lymphoproliferative Disorders, Solid Organ Transplant Complications, Stem Cell Transplant Complications, Epstein-Barr Virus+ Associated Post-Transplant Lymphoproliferative Disease (Ebv+ Ptld), Allogeneic Hematopoietic Cell Transplant | Phase III | Recruiting | A Phase 3 Study of Tabelecleucel for Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease After Failure With Rituximab or Rituximab and Chemotherapy | Dec 29, 2017 | ― |
| Tabelecleucel, Tab-Cel, Ebv-Specific T Cells | Ebv-Induced Lymphomas, Ebv-Associated Malignancies, Transplant Patients With Ebv Viremia At High Risk For Developing A Recurrent Ebv Lymphoma | Phase II | Completed | Therapeutic Effects of Epstein-Barr Virus Immune T-Lymphocytes Derived From a Normal HLA-Compatible Or Partially-Matched Third-Party Donor in the Treatment of EBV Lymphoproliferative Disorders and EBV-Associated Malignancies | Dec 21, 2011 | ― |
| Epstein-Barr Virus-Specific Cytotoxic T Lymphocytes | Ebv-Induced Lymphomas, Ebv-Associated Malignancies, Transplant Patients With Ebv Viremia At High Risk Of Developing A Recurrent Ebv Lymphoma | phase1AndPhase2 | Completed | Biological Therapy in Treating Patients at High-Risk or With Lymphoma, Lymphoproliferative Disease, or Malignancies | Nov 01, 1999 | ― |
| Drug Name | Stage | Condition | Status | Study Name | Trial Start Date | Article |
|---|---|---|---|---|---|---|
| Ata3219 | Phase I | Lupus Nephritis, Systemic Lupus Erythematosus | Withdrawn | A Study to Evaluate the Safety and Preliminary Efficacy of ATA3219 in Participants With Systemic Lupus Erythematosus | May 21, 2024 | ― |
| Ata3219 | Phase I | Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma | Terminated | A Study to Evaluate the Safety and Preliminary Efficacy of ATA3219 in Participants With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma | Feb 05, 2024 | ― |
| Pembrolizumab, Tabelecleucel, Tab-Cel | phase1AndPhase2 | Nasopharyngeal Carcinoma, Nasopharyngeal Neoplasms, Epstein-Barr Virus Infections, Epstein-Barr Viraemia, Epstein-Barr Virus-Associated Nasopharyngeal Carcinoma (Ebv+ Npc) | Terminated | Tabelecleucel in Combination With Pembrolizumab in Subjects With Epstein-Barr Virus-associated Nasopharyngeal Carcinoma (EBV+ NPC) | Nov 29, 2018 | ― |
| Tab-Cel, Ebvallo, Tabelecleucel | Phase III | Lymphoproliferative Disorders, Solid Organ Transplant Complications, Stem Cell Transplant Complications, Epstein-Barr Virus+ Associated Post-Transplant Lymphoproliferative Disease (Ebv+ Ptld), Allogeneic Hematopoietic Cell Transplant | Recruiting | A Phase 3 Study of Tabelecleucel for Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease After Failure With Rituximab or Rituximab and Chemotherapy | Dec 29, 2017 | ― |
| Tabelecleucel, Tab-Cel, Ebv-Specific T Cells | Phase II | Ebv-Induced Lymphomas, Ebv-Associated Malignancies, Transplant Patients With Ebv Viremia At High Risk For Developing A Recurrent Ebv Lymphoma | Completed | Therapeutic Effects of Epstein-Barr Virus Immune T-Lymphocytes Derived From a Normal HLA-Compatible Or Partially-Matched Third-Party Donor in the Treatment of EBV Lymphoproliferative Disorders and EBV-Associated Malignancies | Dec 21, 2011 | ― |
| Epstein-Barr Virus-Specific Cytotoxic T Lymphocytes | phase1AndPhase2 | Ebv-Induced Lymphomas, Ebv-Associated Malignancies, Transplant Patients With Ebv Viremia At High Risk Of Developing A Recurrent Ebv Lymphoma | Completed | Biological Therapy in Treating Patients at High-Risk or With Lymphoma, Lymphoproliferative Disease, or Malignancies | Nov 01, 1999 | ― |
FAQ
What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases: a. Preclinical testing b. Phase 1 – Safety and dosage c. Phase 2 – Effectiveness and side effects d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does Atara Biotherapeutics Inc (DE:AT20) have in its pipeline
Atara Biotherapeutics DE:AT20 is currently developing the following drugs: Ata3219, Pembrolizumab, Tabelecleucel, Tab-Cel, Tab-Cel, Ebvallo, Tabelecleucel, Tabelecleucel, Tab-Cel, Ebv-Specific T Cells, Epstein-Barr Virus-Specific Cytotoxic T Lymphocytes. These drug candidates are in various stages of clinical development as the company works toward FDA approval.